Scarica l'app Stockscreener
46.60
6.08%
2.67
Dopo l'orario di chiusura:
46.94
0.34
+0.73%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$43.93
Aprire:
$46.69
Volume 24 ore:
13.08M
Relative Volume:
1.13
Capitalizzazione di mercato:
$18.21B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-5.3379
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
+15.03%
1M Prestazione:
+11.40%
6M Prestazione:
+65.90%
1 anno Prestazione:
+30.35%
Intervallo 1D:
$45.66
$47.68
Intervallo di 1 settimana:
$38.82
$47.68
Portata 52W:
$22.28
$55.20
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
46.60 | 17.16B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.31 | 121.26B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
792.16 | 83.89B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
845.35 | 52.20B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.68 | 44.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
359.05 | 39.27B | 4.98B | 69.60M | 525.67M | 0.5198 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
FDA will review Moderna’s new flu shot after all - Morning Brew
Moderna’s new flu vaccine to undergo review by FDA | Health Watch - CBS News
Moderna says the FDA will consider its new flu shot after resolving a public dispute - Griffin Daily News
FDA Reverses Decision About Moderna Flu Vaccine - The Bulwark
Stock Movers: eBay, Moderna, Vita Coco - Bloomberg
FDA’s abrupt flip-flop on Moderna’s mRNA flu shot highlights growing risks to drug-makers of investing in vaccines - The Conversation
Moderna Loses 2 Defenses In Patent Fight - GuruFocus
FDA reverses course, will review Moderna’s flu vaccine application - Honolulu Star-Advertiser
Market Today: Moderna rebounds; oil and gold jump - GuruFocus
3 Once-in-a-Decade Buying Opportunities - The Motley Fool
Moderna gets a win from the FDA, but political headwinds remain a concern for vaccine makers - The Boston Globe
Moderna’s flu vaccine back in play as FDA shifts course on review - BioWorld MedTech
FDA Changes Mind, Will Review Moderna MRNA Flu Vaccine - Law360
F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine - The New York Times
Moderna Jumps Above 20-Day Moving Average on FDA Flu Vaccine Review. Should You Buy MRNA Stock Here? - Barchart.com
FDA backtracks on public feud with Moderna and agrees to review mRNA flu vaccine after initial rejection - Fortune
Moderna stock surges as FDA reverses course, agrees to review new flu shot - Yahoo Finance
AI for investors - MLQ.ai
US FDA reverses course, will review Moderna's flu vaccine application | Business Information & News | FE - Westlaw Today
Walmart earnings in focus, Caesars stock surges, Moderna FDA review - Yahoo Finance
Why Moderna (MRNA) Stock Is Trading Up Today - TradingView
Breaking news: The FDA reversed course and agreed to review Moderna’s application for the first mRNA-based flu vaccine under a revised approach, the company announced. In a rare move last week, the agency had declined to review the vaccine. - Facebook
FDA Reverses Course and Will Now Review Moderna’s Flu Shot - The Wall Street Journal
FDA Does 180 On Moderna Flu Vaccine, But Approval Would Come With A Catch - Citeline News & Insights
FDA plans review of Moderna flu vaccine for older adults - upi.com
FDA reverses course and will review Moderna’s mRNA-based flu vaccine - The Guardian
Moderna says FDA will now consider its new mRNA flu shot after initial refusal - PBS
Why Moderna Stock Just Popped - AOL.com
FDA reverses its stance on Moderna flu vaccine review - Medical Economics
FDA reverses course and will review Moderna’s mRNA flu shot, company says - KRDO
In reversal, US FDA will review Moderna's flu vaccine application - Yahoo Finance
FDA Makes U-Turn Again On Moderna New Flu Vaccine Review, Stock Soars - Benzinga
NIH director to temporarily run CDC, New York Times reports - AOL.com
FDA agrees to review Moderna's mRNA flu vaccine after refusal-to-file - WPDE
Moderna Stock Rises. FDA Will Review Its Seasonal Flu Vaccine After All. - Barron's
FDA reverses course on Moderna’s flu vaccine - BioPharma Dive
Moderna says FDA will now review its new flu vaccine, reversing earlier decision - CBS News
FDA to review Moderna's new flu vaccine - breakingthenews.net
FDA reverses course, will review Moderna’s mRNA flu vaccine candidate - The Hill
Moderna (MRNA) Gains from FDA Review of Flu Vaccine Application - GuruFocus
Moderna’s investigational flu vaccine moves forward in FDA review - Proactive financial news
FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal - CNBC
Moderna Loses Two Defenses in Patent Infringement Case Against Arbutus Biopharma - marketscreener.com
FDA will now review flu vaccine it had rejected - Axios
FDA Will Review Moderna's New mRNA Flu Shot - KOA 850 AM & 94.1 FM
U.S. FDA to Initiate Review of Moderna’s Investigational mRNA Flu Vax - Contract Pharma
FDA Reopens Review of Moderna’s mRNA Flu Shot | Newswise - Newswise
Moderna got the FDA to change its mind and review its flu vaccine after some concessions - MarketWatch
Moderna Stock Pops as FDA Application Moves Forward - Schaeffer's Investment Research
FDA Reverses Course on Moderna’s mRNA Flu Shot Application, Promising August Decision - BioSpace
Is Moderna Inc (MRNA) Set to Underperform? Analyzing the Factors Limiting Growth - GuruFocus
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):